COLARIS® assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine (endometrial) cancer. COLARIS® detects mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes. These are the gene mutations that are responsible for the vast majority of Lynch Syndrome and MYH-associated polyposis (MAP) cases.
Colorectal Cancer, Endometrial Cancer
EPCAM (Epithelial cell adhesion molecule), MLH1 (MutL homolog 1), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), MUTYH (MutY homolog), PMS2 (PMS1 protein homolog 2)
Comparative Genomic Hybridization (CGH)